The Drug Controller General of India (DCGI) has granted permission to Biological E Limited to conduct Phase 2 and 3 clinical trials for its Covid19 vaccine, Corbevax on children.

According to a media report, the clinical trial will be carried out on children between 5 and 18 years of age with certain conditions.

After the recommendation from the Subject Expert Committee, the DCGI gave permission to Biological E on Wednesday.

It has been reported that the trial will be conducted in 10 locations across the country.

Biological E has been made an advance payment of Rs 1,500 crore by the central government for 30 crore vaccines.

The trials of Bharat Biotech’s Covid19 vaccine Covaxin for phases 2 and 3 for children are underway, the report said and the results are expected this month.

The needle-free Covid19 vaccine ZyCoV-D Zydus of Cadila has already received emergency use authorisation (EUA) to inoculate children in the age group of 12-18.

It is expected that the vaccine would be administered from the first week of October.

Meanwhile, more than 81 lakh doses of Covid19 have been administered across the country in the last 24 hours.

A total of 66.30 crore vaccine doses have been administered so far under the Nationwide Vaccination Drive.

India has registered a total of 47,092 new Covid19 cases in the last 24 hours

Active cases account for 1.19% of total Covid19 cases.

India’s active caseload stands at 3,89,583 while the country’s recovery rate currently stands at 97.48%.

The country has registered 35,181 recoveries in the last 24 hours.

Avatar photo


Northeast Now is a multi-app based hyper-regional bilingual news portal. Mail us at: